soul trial oral semaglutide cardiovascular outcomes 2024 results mace 🧿 is the first oral GLP-1 SOUL Trial (NEJM 2025): Oral

GIP supplementation was also shown to be ineffective in the 1990s when intravenous (IV) GIP was introduced to hyperglycemic patients with no effect on their blood glucose though physiologic rather than pharmacologic concentrations were supplied [20]

Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases

Now a major meta analysis of randomized placebo-controlled trials has concluded that GLP-1 agonists probably have little or no effect on the risk of obesity-related cancers such as breast cancer

Increased risk of pneumonia among patients with inflammatory bowel disease

Exposure to certain toxins, such as pesticides, heavy metals, and industrial chemicals, has been shown to have a detrimental effect on sperm quality

Intensive Lifestyle Intervention: Another study showed an additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention alongside tirzepatide